NOVEL DRUG DELIVERY SYSTEMS: A TEACHER’S COMPREHENSIVE GUIDE
Welcome, future pharmaceutical scientists and innovators!
A Novel Drug Delivery System (NDDS) is referred to as a fresh approach that combines inventive development, formulations, new technologies, and novel methodologies for supplying pharmaceutical mixtures in the body as required to safely achieve its anticipated pharmacological effects. It may include scientific site-targeting within the body, improved drug potency, and controlled drug discharge with extended pharmacological effect.
As a pharmacy educator with years of experience teaching pharmaceutical technology and drug delivery systems, I have observed that students often find novel drug delivery systems fascinating yet complex. Let me tell you: Novel drug delivery systems are the future of medicine—they have the potential to revolutionise how we treat diseases by delivering drugs precisely where they are needed, when they are needed.
In this comprehensive guide, I will walk you through the fundamentals of novel drug delivery systems—drug delivery carriers (micelles, liposomes, dendrimers, liquid crystals, nanoparticles, solid lipid nanoparticles, hydrogels) and classification of NDDS (sustained release, microencapsulation, parenteral controlled release, buccal, transdermal, ocular, nasal, pulmonary, intra-uterine, gastrointestinal, targeted, nanocarrier, and implantable systems). By the end of this article, you will have a thorough understanding of these innovative drug delivery approaches. Let us begin!
Dpharmguru’s exam insights:
Novel Drug Delivery Systems are frequently tested in pharmacy exams. Remember: NDDS includes sustained release, targeted delivery, and carrier-based systems. Drug delivery carriers include micelles, liposomes, dendrimers, nanoparticles, and hydrogels. Liposomes are phospholipid vesicles. Nanoparticles are 10–200 nm in size. Transdermal patches deliver drugs through the skin. These are classic exam questions!
7.1. DRUG DELIVERY CARRIERS
Any substrate used in the drug delivery process to enhance the safety, efficacy, and/or selectivity of drug administration is referred to as a drug carrier.
7.1.1. Micelles
Micelles are formed by self-assembly of amphiphilic block copolymers (5–50 nm) in aqueous solutions. Drugs can be entrapped in the core of block copolymer micelles and transported at concentrations that exceed their intrinsic water-solubility.
Advantages:
- Provide target specificity
- Biocompatible
- Biodegradable
- Provide controlled release of hydrophilic cancer drugs
Disadvantages:
- Poor drug loading efficiency
- Poor physical stability in-vivo
- Poor solubility
7.1.2. Liposomes
Liposomes are vesicles that contain either of many, few or just one phospholipid bilayer. The polar nature of the liposomal core enables polar drug molecules to be encapsulated. Niosomes are formed when non-ionic surfactants participate instead of phospholipids.
Advantages:
- Harmless, biocompatible, eco-friendly, non-immunogenic
- Increase efficacy and therapeutic index of drugs (e.g., Actinomycin)
- Flexible to bind with site-specific ligands for active targeting
- Facilitate site-specific targeting of anti-cancer, anti-inflammatory drugs
- Great penetration into tissues (Corticosteroids, anaesthetics, insulin)
Disadvantages:
- Short half-life
- High production cost
- May cause leakage of drug in certain cases
7.1.3. Dendrimers
Dendrimers are nanometer-sized, highly branched and monodisperse macromolecules with uniform construction containing a central core, branching units and terminal functional groups.
Advantages:
- Biocompatible
- Enhance solubility of poorly soluble drugs
- Ideal active excipients
Disadvantages:
- High non-specific toxicity
- Low water-solubility
7.1.4. Liquid Crystals
Liquid crystals have both properties of liquid and solid states. They can form different geometries with substitute polar and non-polar layers where aqueous drug solutions can be involved.
Advantages:
- Provide controlled drug delivery
- Enhance stability
- Increase hydration
- Greater surface area for drug contents
Disadvantage: Very high viscosity
7.1.5. Nanoparticles
Nanoparticles (including nanospheres and nanocapsules of size 10–200 nm) are in the solid state and can either be amorphous or crystalline. They can adsorb and encapsulate a drug, thus protecting it from chemical and enzymatic degradation.
Nanodevices for drug delivery: Nanotubes, Quantum dots, Nanorobots, Dendrimers, Nanowires, Nanoshells, Nanonores
Advantages:
- Offer uniform drug delivery with greater bioavailability
- Can be injected via different routes
- High surface area with small size
- Ensure low drug dose
Disadvantages:
- Increase pollution
- May cause inflammation in the lungs if inhaled
- May cause negative environmental impact
7.1.6. Solid Lipid Nanoparticles
Solid Lipid Nanoparticles (SLNs) are the first generation lipid-based nanocarriers produced from lipids. They consist of a solid lipid core matrix that enables solubilisation of lipophilic molecules. They are solids at body temperature, stabilised by emulsifiers, with submicron sizes (<1000 nm).
Advantages:
- Good tolerance
- High bioavailability
- Good biodegradability without toxic product formation
- Extensively used for delivering chemotherapeutic agents into the CNS
Disadvantages:
- Tendency for growth of lipid particles
- Tendency for gel formation
- Less rate of incorporation due to crystalline structure
7.1.7. Hydrogels
Hydrogels are three-dimensional, hydrophilic, polymeric systems capable of absorbing huge amounts of water or biological fluids. They are insoluble due to chemical crosslinks or physical crosslinks. They control drug release in reservoir-based, controlled release systems.
Advantages:
- Injecting biocompatible and biodegradable materials
- Wide degree of flexibility like natural tissue
- Easily modified and transported
Disadvantages:
- Difficult to sterilize due to high water content
- Low stability
- Degrade at a faster rate
7.2. CLASSIFICATION OF NOVEL DRUG DELIVERY SYSTEMS
- Sustained and Controlled Release Drug Delivery
- Microencapsulation
- Parenteral Controlled Release System
- Buccal Drug Delivery System
- Transdermal Drug Delivery System
- Ocular Drug Delivery System
- Nasal Drug Delivery System
- Pulmonary Drug Delivery System
- Intra-Uterine Drug Delivery System
- Gastrointestinal Drug Delivery System
- Targeted Drug Delivery System
- Nanocarriers Drug Delivery System
- Proteins and Peptides
- Implantable Drug Delivery System
7.2.1. Sustained and Controlled Release Drug Delivery
This system delivers drug action at a pre-determined rate by giving a prolonged or constant (Zero-order) discharge at therapeutically effective levels.
Examples: Dextromethorphan (coated), Diclofenac, Nicotine
7.2.2. Microencapsulation
Microencapsulation is a process where small droplets or particles of solid or liquid substances are covered by a continuous film of polymeric materials. The particles range from some tenths of a micron to 5000 microns.
Examples: Lavender oil, Orange oil
7.2.3. Parenteral Controlled Release System
This system reduces the frequency of injection by using formulation technology that promises controlled drug release. Depot formulations are designed to reduce the frequency of injection from daily to once or twice monthly.
Examples: Transdermal patches, Implantable pumps, Intramuscular depot injections
7.2.4. Buccal Drug Delivery System
The buccal region provides a suitable route for systemic drug delivery. Buccal cavity mucosa is the most convenient and available site due to its rich blood supply and relatively permeable nature.
Examples: Buccal patches (Carvedilol hydrochloride), Chitosan film integrating insulin nanoparticles
7.2.5. Transdermal Drug Delivery System
Transdermal Drug Delivery System delivers the drug through the skin at a controlled rate to the systemic circulation when applied on the intact skin.
Examples: Nicotine patches (painkillers), Transdermal clonidine patches (hypertension)
7.2.6. Ocular Drug Delivery System
Conventional eye drops have several disadvantages—injury from bottle tip, bacterial contamination, preservative-induced irritation, and poor pharmacokinetics. NODS (New Ophthalmic Drug Delivery System) is a harmless and tolerated delivery system.
Examples: Ocuserts or ocular inserts (Pilocarpine), Contact lens (Chloramphenicol)
7.2.7. Nasal Drug Delivery System
Nasal administration provides an interesting alternative to the parenteral route. It is suitable when the blood-brain barrier has to be crossed and for the administration of vaccines. It provides rapid systemic drug absorption and quick onset of action.
Examples: Corticosteroid nasal spray, Fluticasone nasal spray
7.2.8. Pulmonary Drug Delivery System
The pulmonary route is used to treat respiratory diseases. It can minimize the required dose compared to other routes. The respiratory tract is sterile below the larynx in healthy people.
Examples: Nebuliser (Albuterol sulphate), Dry powder inhaler (Beclomethasone dipropionate)
7.2.9. Intra-Uterine Drug Delivery System
Intra Uterine Devices (IUDs) are small plastic contraceptive devices inserted into the uterus. They are about 98–99% effective and copper IUDs stay in place for up to 10 years.
Examples: DEPO-Provera, Norplant, Copper bearing IUDs
7.2.10. Gastrointestinal Drug Delivery System
Some drugs have an ‘absorption window’—they are absorbed in specific portions of the gastrointestinal tract. Gastro Retentive Dosage Forms (GRDF) regulate gastric residence time (GRT) to achieve a prolonged drug delivery profile.
Examples: Floating tablets (Acetaminophen, Acetylsalicylic acid), Floating capsules, Floating granules (Diclofenac sodium, Prednisolone)
7.2.11. Targeted Drug Delivery System
Targeted Drug Delivery delivers drugs to specific parts, organs, or receptors of the body. Two distinct approaches are:
- The drug is directly selected for the target site
- The chemical agent is offered but activated only at the target site
Examples: Polysorbate 80 niosomes (gene delivery), Carbon nanotubes (high drug-loading), Liposome encapsulated doxorubicin, vincristine, cisplatin (cancer treatment)
7.2.12. Nanocarrier Drug Delivery System
Nanoparticle drug formulation decreases patient costs and risks of toxicity. Nanocapsulation of drugs (nanomedicines) raises drug efficacy, specificity, and therapeutic index.
Examples: Nanoparticulate drug crystals, Dendritic or hyperbranched polymers such as poly(amidoamine) dendrimers
7.2.13. Implantable Drug Delivery System
Implants are present beneath the skin and permit drugs and fluids into the bloodstream without the constant use of needles. The main disadvantage is the requirement for surgical implantation with the risk of infection.
Examples: Levonorgestrel implants, Etonogestrel implants
7.3. ADVANTAGES OF NDDS
- Provides controlled delivery by sustaining desired drug concentration
- Permits precise dosing
- Exhibits improved efficacy and safety
- Provides site or target-specific delivery with an optimum dose
- Has reduced toxicity/side effects
- Helpful for patients for better comfort and standard of living
7.4. CHALLENGES OF NDDS
- Poorly soluble drugs and bioavailability hurdles
- Protein drug delivery challenges
- Pediatric and geriatric drug supply
- High cost of nanomedicine administration
- Cytotoxicity of nanoparticles
- Partial availability and lesser production rate of personalised medicines
- Risk of acid or enzymatic degradation for oral drugs
- Difficulty in introducing devices in babies or elderly patients
- Drug incompatibility with polymer matrices
Dpharmguru’s exam insights:
NDDS challenges are frequently tested. Remember: Major challenges include delivery of poorly soluble drugs, protein drug delivery, pediatric/geriatric supply, high cost, cytotoxicity, and degradation issues. These are important considerations in the development of novel drug delivery systems.
COMPARISON: DRUG DELIVERY CARRIERS
| Carrier | Size | Key Feature | Main Advantage | Main Disadvantage |
|---|---|---|---|---|
| Micelles | 5–50 nm | Self-assembly of amphiphilic copolymers | Target specificity | Poor drug loading |
| Liposomes | Variable | Phospholipid bilayers | Biocompatible, non-immunogenic | Short half-life |
| Dendrimers | Nanometer-sized | Highly branched macromolecules | Enhance solubility | High non-specific toxicity |
| Nanoparticles | 10–200 nm | Solid state, amorphous/crystalline | Uniform drug delivery | Environmental impact |
| SLNs | <1000 nm | Solid lipid core matrix | High bioavailability | Particle growth |
| Hydrogels | Variable | 3D hydrophilic polymeric system | Flexible, biocompatible | Difficult to sterilize |
FREQUENTLY ASKED QUESTIONS (FAQs)
1. What is a Novel Drug Delivery System (NDDS)?
A Novel Drug Delivery System (NDDS) is a fresh approach that combines inventive development, formulations, and new technologies for supplying pharmaceutical mixtures in the body to safely achieve its anticipated pharmacological effects, including site-targeting, improved drug potency, and controlled drug discharge.
2. What are liposomes?
Liposomes are vesicles that contain phospholipid bilayers. The polar core enables polar drug molecules to be encapsulated. They are biocompatible, non-immunogenic, and facilitate site-specific targeting of anti-cancer and anti-inflammatory drugs.
3. What is the difference between nanoparticles and solid lipid nanoparticles?
Nanoparticles are solid particles (10–200 nm) that can be amorphous or crystalline. Solid Lipid Nanoparticles (SLNs) are lipid-based nanocarriers with a solid lipid core matrix (<1000 nm), used for delivering chemotherapeutic agents into the CNS.
4. What is a transdermal drug delivery system?
A Transdermal Drug Delivery System delivers the drug through the skin at a controlled rate to the systemic circulation when applied on the intact skin. Examples: Nicotine patches, Transdermal clonidine patches.
5. What are the advantages of novel drug delivery systems?
NDDS offers controlled delivery, precise dosing, improved efficacy and safety, site-specific targeting, reduced toxicity, and better patient comfort and quality of life.
6. What are the challenges of novel drug delivery systems?
Challenges include poorly soluble drugs, protein drug delivery, pediatric/geriatric supply, high cost, cytotoxicity, degradation, and drug incompatibility with polymer matrices.
SUMMARY
Novel Drug Delivery Systems are revolutionising pharmaceutical therapy. This guide covered:
- Drug Delivery Carriers: Micelles, Liposomes, Dendrimers, Liquid Crystals, Nanoparticles, SLNs, Hydrogels
- NDDS Classification: Sustained release, Microencapsulation, Parenteral controlled release, Buccal, Transdermal, Ocular, Nasal, Pulmonary, Intra-uterine, Gastrointestinal, Targeted, Nanocarrier, Implantable systems
- Advantages: Controlled delivery, precise dosing, improved efficacy, site-specific targeting, reduced toxicity
- Challenges: Poorly soluble drugs, protein delivery, high cost, cytotoxicity, degradation issues
As I always tell my students: “Novel drug delivery systems are not just about delivering drugs—they are about delivering hope, precision, and a better quality of life to patients.”
REFERENCES AND FURTHER READING
- Pharmacy Council of India (PCI). (2022). Pharmaceutics Syllabus. New Delhi: PCI.
- Aulton, M. E., & Taylor, K. M. G. (2018). Aulton’s Pharmaceutics: The Design and Manufacture of Medicines (5th ed.). Elsevier.
- Allen, L. V., & Ansel, H. C. (2014). Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (10th ed.). Wolters Kluwer.
- Lachman, L., Lieberman, H. A., & Kanig, J. L. (2018). The Theory and Practice of Industrial Pharmacy (4th ed.). CBS Publishers.
- Jain, N. K. (2020). Controlled and Novel Drug Delivery. CBS Publishers.
- Vyas, S. P., & Khar, R. K. (2019). Targeted and Controlled Drug Delivery: Novel Carrier Systems. CBS Publishers.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for medical concerns. Pharmaceutical regulations and guidelines may vary by region—always refer to your local regulatory authorities for specific requirements.
written by:
Dr. N. Sujith Kumar
For More Study Materials, Visit: www.dpharmguru.com
